Add time:09/07/2019 Source:sciencedirect.com
Abacavir (ABC) is a nucleoside HIV-1 reverse transcriptase inhibitor, approved for clinical use in 1998. It is part of the recommended first-line therapy for treating HIV-1 infected children and adolescents. Resistance is determined by the M184V mutation, but additional substitutions are needed to achieve high-level resilience. Toxicity is mainly due to a hypersensitivity reaction syndrome, which is genetically linked to the HLA-B*5701 allele. ABC can be considered a valuable alternative for second-line regimens in experienced adult patients and it is also being considered as first-line therapy in drug naïve HIV-1 infected adults, in combination with dolutegravir and lamivudine.
We also recommend Trading Suppliers and Manufacturers of Abacavir (cas 136470-78-5). Pls Click Website Link as below: cas 136470-78-5 suppliers
About|Contact|Cas|Product Name|Molecular|Country|Encyclopedia
Message|New Cas|MSDS|Service|Advertisement|CAS DataBase|Article Data|Manufacturers | Chemical Catalog
©2008 LookChem.com,License: ICP
NO.:Zhejiang16009103
complaints:service@lookchem.com Desktop View